TY - JOUR
T1 - Bcl-2 and p53 expression in node-negative breast carcinoma
T2 - A study with long-term follow-up
AU - Barbareschi, Mattia
AU - Caffo, Orazio
AU - Veronese, Silvio
AU - Leek, Russel D.
AU - Fina, Paolo
AU - Fox, Steven
AU - Bonzanini, Mariella
AU - Girlando, Salvatore
AU - Morelli, Luca
AU - Eccher, Claudio
AU - Pezzella, Francesco
AU - Doglioni, Claudio
AU - Dalla Palma, Paolo
AU - Harris, Adrian
PY - 1996
Y1 - 1996
N2 - Bcl-2 and p53 gene products (Bcl-2, p53) are important regulators of apoptosis and cell proliferation, and their immunohistochemical expression may help to identify high-risk breast cancer patients. The authors evaluated p53 and Bcl-2 immunoreactivity in 178 node-negative breast cancers (NNBC) with long-term follow-up (median, 60 months). Bcl-2 was seen in 111 (62%) cases, and was significantly associated with small tumor size, nonductal morphology, low tumor grade, estrogen-receptor (ER) positivity, and p53 negativity. p53 overexpression (ie, >15% reactive nuclei) was observed in 31 (17%) cases, and was associated with lower age, large tumor size, ductal morphology, high tumor grade, negative ER status, and lack of Bcl-2 immunoreactivity. In univariate analysis, the variables associated with short relapse-free survival (RFS) were large tumor size (P = .002), high histological grade (P = .01), high mitotic count (P = .03), and high Nottingham prognostic index (NPI) (P = .0002). In multivariate analysis (final mode)), only the NPI was of independent prognostic value concerning RFS.
AB - Bcl-2 and p53 gene products (Bcl-2, p53) are important regulators of apoptosis and cell proliferation, and their immunohistochemical expression may help to identify high-risk breast cancer patients. The authors evaluated p53 and Bcl-2 immunoreactivity in 178 node-negative breast cancers (NNBC) with long-term follow-up (median, 60 months). Bcl-2 was seen in 111 (62%) cases, and was significantly associated with small tumor size, nonductal morphology, low tumor grade, estrogen-receptor (ER) positivity, and p53 negativity. p53 overexpression (ie, >15% reactive nuclei) was observed in 31 (17%) cases, and was associated with lower age, large tumor size, ductal morphology, high tumor grade, negative ER status, and lack of Bcl-2 immunoreactivity. In univariate analysis, the variables associated with short relapse-free survival (RFS) were large tumor size (P = .002), high histological grade (P = .01), high mitotic count (P = .03), and high Nottingham prognostic index (NPI) (P = .0002). In multivariate analysis (final mode)), only the NPI was of independent prognostic value concerning RFS.
KW - Bcl-2
KW - breast cancer
KW - estrogen receptors
KW - human
KW - immunohistochemistry
KW - p53 protein
KW - survival analysis
UR - http://www.scopus.com/inward/record.url?scp=16044367682&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=16044367682&partnerID=8YFLogxK
U2 - 10.1016/S0046-8177(96)90307-X
DO - 10.1016/S0046-8177(96)90307-X
M3 - Article
C2 - 8912823
AN - SCOPUS:16044367682
VL - 27
SP - 1149
EP - 1155
JO - Human Pathology
JF - Human Pathology
SN - 0046-8177
IS - 11
ER -